Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
Open Access
- 1 December 2013
- journal article
- review article
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. 6, 877-95
- https://doi.org/10.2147/ijgm.s51665
Abstract
Peer reviewed article authored by (Gerich J). Read article or submit your manuscript for publishing.Keywords
This publication has 99 references indexed in Scilit:
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical developmentContemporary Clinical Trials, 2011
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialThe Lancet, 2010
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialThe Lancet, 2010
- Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 DiabetesAmerican Journal Of Medicine, 2010
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Diabetologia, 2010
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylureaDiabetes Research and Clinical Practice, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetesClinical Therapeutics, 2008